Health

STAT+: What to know about Biogen’s big lupus study readout

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 12/11/2026, 11:36:24 UTC.

Briefings

Biogen is evaluating two lupus drugs, dapirolizumab and litifilimab, in Phase 3 studies. The first drug showed positive results in a Phase 3 study, while the second is currently being evaluated. CEO Chris Viehbacher implemented a new R&D strategy in 2022 that is being tested through these upcoming readouts.

Key points

• Biogen is evaluating two lupus drugs, dapirolizumab and litifilimab, in Phase 3 studies.
• CEO Chris Viehbacher implemented a new R&D strategy in 2022 that is being tested through these upcoming readouts.

Context

This story first appeared in Adam's Biotech Scorecard, a STAT newsletter. The drug dapirolizumab showed positive results in a Phase 3 study, while litifilimab is currently being evaluated in twin Phase 3 studies. CEO Chris Viehbacher implemented a new R&D strategy in 2022 that is being tested through these upcoming readouts.

Limitations

Evidence is limited to a STAT newsletter article from 2026. No specific dates, numbers, or outcomes for litifilimab are provided. The article does not contain direct quotes or causal claims beyond stating Biogen's strategy is being tested.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 12/11/2026, 13:14:56 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifljmo6zoahzmktpj37qzkos272l76cdvpbym6xlt2zpoouzj4bem